Economics and risks of FDA's Quality management maturity rating programme
The introduction of pharmaceutical manufacturing quality ratings by the FDA under its Quality Management Maturity (QMM) programme has the potential to reduce drug shortages and improve pharmaceutical company financial performance. Here, Dr Clifford Rossi of the University of Maryland explains.
United States Clifford Rossi Journal Of Health Economics Citigroup Consumer Lending Group Group Purchasing Organisations Gpos University Of Maryland
Source: europeanpharmaceuticalreview.com